ORPHAN DRUGS

BY KEITH NUTHALLTHE FINAL stage of the new EU procedure to approve orphan drugs has been completed, with the European Agency for the Evaluation of Medicinal Products, (EMEA), publishing the first summaries of positive opinions regarding these specialist medicines. Under the procedure, which promotes the development of orphan drugs by granting pharmaceutical companies special intellectual property rights, publication follows official designation of a medicine by the European Commission. Opinions have now been released for drugs including fumagillin, (for the ...


Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.